In a prospective analysis, researchers determined the effect of poor oral health on pain presentations in women.

Researchers compared the efficacy of medication-overuse headache treatment strategies, with a focus on reduction in monthly headache days.

Researchers estimated the real-world risk for cardiovascular events associated with erenumab and other migraine preventive medications.

Researchers conducted a systematic review and meta-analysis to compare lasmiditan vs triptans for the treatment of menstrual migraine.

Researchers conducted a cohort study to examine the association between semaglutide use and risk for NAION among patients with diabetes.

Researchers examined associations between self-reported oral health, the oral microbiome, and various pain presentations in women.

Researchers developed best practice advice to inform clinicians about the benefits and harms of cannabis or cannabinoids in the management of chronic noncancer pain.

Researchers conducted a systematic review to examine the benefits and harms of acute pain interventions among patients with OUD.

Researchers conducted a cross-sectional survey to gauge the effect of diabetic peripheral neuropathy with and without pain on quality of life.

Researchers sought to assess the risk for attempted and completed suicide associated with a diagnosis of migraine, tension-type headache, posttraumatic headache, and trigeminal autonomic cephalalgia.

Researchers sought to assess the efficacy and safety of atogepant in episodic migraine and chronic migraine and functional outcomes during the first 4 weeks of treatment.

In a post hoc analysis, researchers evaluated the proportion of patients who shifted from chronic to episodic migraine when treated with galcanezumab vs placebo.

Researchers examined zonisamide prophylaxis and reduction in HDPM in pediatric patients with migraine in a retrospective cohort study conducted at a single institution.

Researchers evaluated the effects of zavegepant nasal spray vs placebo on migraine-associated pain and disability during a 48-hour period.

Overall, the analysis showed lower stroke rates among female propranolol users at multiple timepoints.

The US Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

Compared with non-Hispanic White (NHW) children, non-Hispanic Black (NHB) and Hispanic/Latino (HL) children with a headache diagnosis in the emergency department have lower rates of migraine diagnosis.

Researchers compared the efficacy and safety of pregabalin vs gabapentin among patients with neuropathic pain.

The pooled prevalence of chronic painful neuropathy is 41.22% among individuals with chemotherapy-induced peripheral neuropathy (CIPN).

Researchers assessed the risk for migraine and other headache types in women who later developed multiple sclerosis.

Propranolol is associated with a reduced risk for overall stroke among women with migraine, with a more pronounced protective effect for ischemic stroke.

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Many very preterm infants experience pain, according to a study published online.

Researchers evaluated the global rates of incidence, prevalence, and disability-adjusted life years of migraine from 1990 to 2021.

Researchers assessed physiologic changes of the spine as well as the frequency of low back pain among astronauts during and after spaceflight.

Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with overweight/obesity.